Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16698299 | 0.89 | GPBAR1 (0.65) | GPBAR1HSD17B10NR1H4ALDH1A1KMT2A | |
| SCHEMBL25942183 | 0.85 | GPBAR1 (0.52) | GPBAR1HSD17B10NR1H4ALDH1A1KMT2A | |
| SCHEMBL19899899 | 0.85 | NR1H4 (0.55) | GPBAR1NR1H4ALDH1A1LMNATSHR | |
| SCHEMBL30437797 | 0.82 | NR1H4 (0.51) | GPBAR1NR1H4 | |
| SCHEMBL19899996 | 0.82 | NR1H4 (0.51) | GPBAR1NR1H4 | |
| SCHEMBL30605724 | 0.82 | GPBAR1 (0.62) | GPBAR1HSD17B10NR1H4ALDH1A1KMT2A | |
| SCHEMBL16697733 | 0.82 | GPBAR1 (0.62) | GPBAR1HSD17B10NR1H4ALDH1A1KMT2A | |
| SCHEMBL19900432 | 0.82 | KMT2A (0.46) | GPBAR1NR1H4KMT2ALMNAHTT | |
| SCHEMBL21456306 | 0.80 | NR1H4 (0.51) | NR1H4ALDH1A1LMNATSHR | |
| SCHEMBL25942214 | 0.80 | NR1H4 (0.59) | GPBAR1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | GPBAR1 9/4885HSD17B10 2510/4885NR1H4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.